Back to top
more

Kadmon Holdings, Inc. (KDMN)

(Delayed Data from NYSE)

$2.33 USD

2.33
605,406

+0.08 (3.56%)

Updated May 3, 2019 04:02 PM ET

After-Market: $2.32 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kadmon Holdings, Inc. (KDMN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Kadmon Holdings, Inc. (KDMN) delivered earnings and revenue surprises of 0.00% and 3393.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Kadmon Holdings, Inc. (KDMN) Q3 Earnings Expected to Decline

by Zacks Equity Research

Kadmon Holdings, Inc. (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health

by Kinjel Shah

Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.

Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study

by Zacks Equity Research

Sanofi's (SNY) rilzabrutinib fails to meet the primary endpoint in a phase III study. It was added to its portfolio following the acquisition of Principia Biopharma last year.

Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock

by Zacks Equity Research

Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.

Implied Volatility Surging for Kadmon Holdings (KDMN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Kadmon Holdings (KDMN) stock based on the movements in the options market lately.

Kadmon Holdings, Inc. (KDMN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kadmon Holdings, Inc. (KDMN) delivered earnings and revenue surprises of 0.00% and -42.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Kadmon Holdings, Inc. (KDMN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Kadmon Holdings, Inc. (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kadmon Holdings, Inc. (KDMN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Kadmon Holdings, Inc. (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kadmon Holdings, Inc. (KDMN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Kadmon Holdings, Inc. (KDMN) delivered earnings and revenue surprises of 0.00% and 37.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for August 28th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

New Strong Sell Stocks for September 8th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Implied Volatility Surging for Kadmon (KDMN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Kadmon (KDMN) stock based on the movements in the options market lately.

Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD

by Zacks Equity Research

Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).

Will Kadmon Holdings (KDMN) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Kadmon Holdings (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moleculin Files New Patents for Cancer Candidate Annamycin

by Zacks Equity Research

Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.

Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug

by Zacks Equity Research

Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).

Will Kadmon Holdings (KDMN) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Kadmon Holdings (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kadmon Holdings (KDMN) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Kadmon Holdings, Inc. (KDMN).

    Kadmon Holdings (KDMN) Jumps: Stock Rises 9.3%

    by Zacks Equity Research

    Kadmon Holdings, Inc. (KDMN) was a big mover last session, as the company saw its shares more than 9% on the day amid huge volumes.

      Kadmon Holdings (KDMN) Shares March Higher, Can It Continue?

      by Zacks Equity Research

      Kadmon Holdings Inc (KDMN) has been on the move lately as the stock has risen by 76.9% in the past four weeks, and it is currently trading well above its 20-Day SMA